MX2018005088A - Formulaciones de fenilacetato de l-ornitina. - Google Patents

Formulaciones de fenilacetato de l-ornitina.

Info

Publication number
MX2018005088A
MX2018005088A MX2018005088A MX2018005088A MX2018005088A MX 2018005088 A MX2018005088 A MX 2018005088A MX 2018005088 A MX2018005088 A MX 2018005088A MX 2018005088 A MX2018005088 A MX 2018005088A MX 2018005088 A MX2018005088 A MX 2018005088A
Authority
MX
Mexico
Prior art keywords
ornithine phenylacetate
liver
patients
oral formulations
formulation
Prior art date
Application number
MX2018005088A
Other languages
English (en)
Inventor
Wang Laurene
S Grais Linda
Bukofzer Stanley
Original Assignee
Ocera Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/133,087 external-priority patent/US20160338982A1/en
Application filed by Ocera Therapeutics Inc filed Critical Ocera Therapeutics Inc
Publication of MX2018005088A publication Critical patent/MX2018005088A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Algunas modalidades de la presente solicitud se refieren a formulaciones orales de fenilacetato de L-ornitina y métodos para usar las mismas. Estas formulaciones orales ofrecen ruta alternativa de administración que la administración intravenosa estándar de fenilacetato de Lornitina para tratar hiperamonemia en pacientes que tienen enfermedades y trastornos agudos y crónicos del hígado, por ejemplo, falla hepática aguda, descompensación hepática, hipertensión portal, encefalopatía hepática, o pacientes con trastornos del ciclo de urea.
MX2018005088A 2015-11-13 2016-11-11 Formulaciones de fenilacetato de l-ornitina. MX2018005088A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562255300P 2015-11-13 2015-11-13
US201662276754P 2016-01-08 2016-01-08
US15/133,087 US20160338982A1 (en) 2015-04-20 2016-04-19 Formulations of l-ornithine phenylacetate
PCT/US2016/061678 WO2017083758A1 (en) 2015-11-13 2016-11-11 Formulation of l-ornithine phenylacetate

Publications (1)

Publication Number Publication Date
MX2018005088A true MX2018005088A (es) 2019-05-16

Family

ID=58695607

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018005088A MX2018005088A (es) 2015-11-13 2016-11-11 Formulaciones de fenilacetato de l-ornitina.
MX2022001517A MX2022001517A (es) 2015-11-13 2018-04-25 Formulaciones de fenilacetato de l-ornitina.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022001517A MX2022001517A (es) 2015-11-13 2018-04-25 Formulaciones de fenilacetato de l-ornitina.

Country Status (12)

Country Link
EP (1) EP3373923A4 (es)
JP (2) JP7294807B2 (es)
KR (1) KR20180086431A (es)
CN (2) CN113768863A (es)
AU (2) AU2016353350B2 (es)
BR (1) BR112018009349A8 (es)
CA (1) CA3004331A1 (es)
IL (1) IL258630B2 (es)
MX (2) MX2018005088A (es)
RU (1) RU2018113801A (es)
SG (1) SG11201802987UA (es)
WO (1) WO2017083758A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
PE20200747A1 (es) 2017-08-14 2020-07-24 Axcella Health Inc Composiciones de aminoacidos para el tratamiento de enfermedad hepatica
MA52971A (fr) 2018-06-20 2021-04-28 Axcella Health Inc Compositions et procédés pour le traitement de l'infiltration de graisse dans le muscle
AU2020366365A1 (en) * 2019-10-16 2022-04-21 Mallinckrodt Enterprises Llc Dosages and uses of ornithine phenylacetate for treating hyperammonemia

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4783443A (en) 1986-03-03 1988-11-08 The University Of Chicago Amino acyl cephalosporin derivatives
ES2537974T3 (es) 2004-11-26 2015-06-16 Ucl Business Plc Composiciones que comprenden ornitina y fenilacetato o fenilbutirato para el tratamiento de la encefalopatía hepática
GB0426141D0 (en) * 2004-11-26 2004-12-29 Ucl Biomedica Plc Treatment
DE102007009243A1 (de) * 2007-02-22 2008-09-18 Evonik Röhm Gmbh Pellets mit einer Wirkstoff-Matrix und einem Polymerüberzug, sowie ein Verfahren zur Herstellung der Pellets
AU2015221466B2 (en) 2009-04-03 2017-02-02 Ocera Therapeutics, Inc. L-ornithine phenyl acetate and methods of making thereof
WO2010115055A1 (en) * 2009-04-03 2010-10-07 Ocera Therapeutics, Inc. L-ornithine phenyl acetate and methods of making thereof
AU2014250643B2 (en) 2009-06-08 2016-07-14 Ocera Therapeutics, Inc. Treatment of portal hypertension and restoration of liver function using L-ornithine phenylacetate
DK2440200T3 (en) 2009-06-08 2014-12-08 Ucl Business Plc Treatment of portal hypertension in the application of l-ornithinphenylacetat
NZ609191A (en) * 2010-10-06 2015-06-26 Ocera Therapeutics Inc Methods of making l-ornithine phenyl acetate
CN103705490B (zh) * 2013-10-31 2016-08-17 蚌埠丰原医药科技发展有限公司 一种门冬氨酸鸟氨酸的缓释制剂及其制备工艺
DK3285756T3 (da) 2015-04-20 2023-05-08 Ocera Therapeutics Inc Formuleringer af l-ornithinphenylacetat

Also Published As

Publication number Publication date
IL258630B1 (en) 2023-04-01
CN108366983A (zh) 2018-08-03
WO2017083758A1 (en) 2017-05-18
AU2016353350A1 (en) 2018-05-10
CA3004331A1 (en) 2017-05-18
AU2021290236A1 (en) 2022-02-10
AU2016353350B2 (en) 2021-09-23
EP3373923A4 (en) 2019-07-03
MX2022001517A (es) 2022-11-16
JP7294807B2 (ja) 2023-06-20
EP3373923A1 (en) 2018-09-19
IL258630A (en) 2018-06-28
CN113768863A (zh) 2021-12-10
BR112018009349A8 (pt) 2019-02-26
RU2018113801A (ru) 2019-12-16
JP2018533601A (ja) 2018-11-15
JP2022058446A (ja) 2022-04-12
KR20180086431A (ko) 2018-07-31
IL258630B2 (en) 2023-08-01
BR112018009349A2 (pt) 2018-11-13
SG11201802987UA (en) 2018-05-30

Similar Documents

Publication Publication Date Title
MX2022003855A (es) Formulaciones de fenilacetato de l-ornitina.
MX2022001517A (es) Formulaciones de fenilacetato de l-ornitina.
MY196173A (en) Cot Modulators And Methods Of Use Thereof
MA42950A (fr) Administration d'agents de potentialisation de cftr modifiés au deutérium
TN2014000476A1 (en) D-amino acid compounds for liver disease
MX2019011219A (es) Administracion rapida y controlada de composiciones con efectos sequito restaurados.
BR112014032699A2 (pt) métodos de tratamento de síndrome metabólica pediátrica
CL2019002190A1 (es) Reducción de la viscosidad de formulaciones farmacéuticas que comprende una proteína terapéutica a una concentración de al menos 70 mg/ml, donde la proteína terapéutica no es un anticuerpo (divisional solicitud 201700984)
MX371093B (es) Compuestos de microarn y metodos para modular al mir-122.
PH12015502588A1 (en) 4`-fluoro-2`-methyl substituted nucleoside derivatives
RS54584B1 (en) 15-HEPE PREPARATIONS AND PROCEDURES FOR THEIR USE
UY36586A (es) Heterociclilmetiltienouracilos y uso de los mismos
BR112015017251A2 (pt) composições farmacêuticas compreendendo doadores de nitroxil
BR112016020181A8 (pt) composições de ácido lipoico éster colina e métodos de uso.
EA201691918A1 (ru) Фармацевтические составы ингибитора киназ семейства raf, способы их получения и способы их применения
MX2018007871A (es) Composiciones para el cuidado personal.
BR112016007238A2 (pt) tienouracilcarboxamidas cíclicas e sua utilização
NZ713440A (en) Nsaid administration and related compositions, methods and systems.
WO2014194053A3 (en) Carbohydrate compounds for nutritional and therapeutic use
BR112015015855A2 (pt) composições líquidas de stévia
PH12018500895A1 (en) Formulation of l-ornithine phenylacetate
MX2021001361A (es) Composicion liquida de fibrinogeno humano.
GB2527233A (en) Composition comprising hydrocortisone
MX2022004449A (es) Dosis y usos de fenilacetato de ornitina para el tratamiento de hiperamonemia.
BR112018004244A2 (pt) formulações sólidas de pirofosfato férrico solúvel, kits e seus métodos de uso